中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Naturally sourced amphiphilic peptides as paclitaxel vehicles for breast cancer treatment

文献类型：期刊论文

作者Chen, Rongli6,7; Liu, Ergang6; Fang, Yuefei6; Gao, Nan6; Zhang, Meng5; Zhang, Xiaoru4,6; Chen, Wanying4; Liang, Chuxin6; Zhang, Yu7; Huang, Yongzhuo1,2,3,6
刊名BIOMATERIALS ADVANCES
出版日期2024-05-01
卷号159页码:12
关键词Breast cancer Amphiphilic peptide Micelles Drug delivery Paclitaxel
DOI10.1016/j.bioadv.2024.213824
通讯作者Liu, Ergang(liuergang@zidd.ac.cn) ; Zhang, Yu(pharmzy@163.com) ; Huang, Yongzhuo(yzhuang@simm.ac.cn)
英文摘要The marketed paclitaxel (PTX) formulation Taxol relies on the application of Cremophor EL as a solubilizer. The major drawback of Taxol is its hypersensitivity reactions and a pretreatment of anti-allergic drugs is a necessity. Therefore, developing an efficient and safe delivery vehicle is a solution to increase PTX treatment outcomes with minimal adverse effects. In this work, we prepared the amphiphilic peptides (termed AmP) from soybean proteins using a facile two-step method. AmP could efficiently solubilize PTX by self-assembling into mixed micelles with D- alpha-tocopherol polyethylene glycol succinate (TPGS), a common pharmaceutical expedient (PTX@TPGSAmP). The intravenously administrated PTX@TPGS-AmP exhibited a slow clearance (0.24 mL & sdot; (min & sdot; kg) - 1 ) and an enhanced AUC (41.4 mu g.h/mL), manifesting a 3.6-fold increase compared to Taxol. In a murine 4T1 tumor model, PTX@TPGS-AmP displayed a superior antitumor effect o v er Taxol. Importantly, safety assessment showed a high biocompatibility of AmP and an i.v. dose up to 2500 mg/kg led to no observable abnormalities in the mice. In summary, the AmP presents a new green and easily-prepared amphiphilic biomaterial, with promising potential as a pharmaceutical excipient for drug delivery.
WOS关键词VITAMIN-E TPGS ; MIXED MICELLES ; POLYMERIC MICELLES ; IN-VITRO
资助项目National Key Research and Development Program of China[2021YFE0103100] ; National Key Research and Development Program of China[2021YFC2400600] ; NFSC[81925035] ; NFSC[82341232] ; Department of Science and Technology of Guangdong Province[2019B090904008] ; Department of Science and Technology of Guangdong Province[2021B0909050003] ; Sci-Tech Innovation Projects in Zhongshan City[LJ2021001] ; Sci-Tech Innovation Projects in Zhongshan City[CXTD2022011]
WOS研究方向Materials Science
语种英语
WOS记录号WOS:001217342400001
出版者ELSEVIER
源URL[http://119.78.100.183/handle/2S10ELR8/311343]  
专题新药研究国家重点实验室
通讯作者Liu, Ergang; Zhang, Yu; Huang, Yongzhuo
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
2.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipie, Shanghai 201203, Peoples R China
3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
4.Guangzhou Univ Chinese Med, Artemisinin Res Ctr, Guangzhou 510450, Peoples R China
5.Zhejiang Univ, Womens Hosp, Dept Pharm, Sch Med, Hangzhou 310006, Peoples R China
6.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China
7.Shenyang Pharmaceut Univ, Shenyang 110016, Peoples R China
推荐引用方式
GB/T 7714		 Chen, Rongli,Liu, Ergang,Fang, Yuefei,et al. Naturally sourced amphiphilic peptides as paclitaxel vehicles for breast cancer treatment[J]. BIOMATERIALS ADVANCES,2024,159:12.
APA Chen, Rongli.,Liu, Ergang.,Fang, Yuefei.,Gao, Nan.,Zhang, Meng.,...&Huang, Yongzhuo.(2024).Naturally sourced amphiphilic peptides as paclitaxel vehicles for breast cancer treatment.BIOMATERIALS ADVANCES,159,12.
MLA Chen, Rongli,et al."Naturally sourced amphiphilic peptides as paclitaxel vehicles for breast cancer treatment".BIOMATERIALS ADVANCES 159(2024):12.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。